Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

NCT04141150 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease
Mild Cognitive Impairment Due to Alzheimer's Disease
Healthy Volunteers

Interventions

DRUG: [18F]APN-1607

Sponsor

APRINOIA Therapeutics, LLC